NCT00969150 - Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder | Biotech Hunter

Enrollment

362

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2010

Conditions

Major Depressive Disorder

Interventions

DRUG

Levomilnacipran ER

Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.

DRUG

Placebo

Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

Trial Locations (25)

10021

Forest Investigative Site, New York

10312

Forest Investigative Site, Staten Island

11235

Forest Investigative Site, Brooklyn

19107

Forest Investigative Site, Philadelphia

21061

Forest Investigative Site, Glen Burnie

32216

Forest Investigative Site, Jacksonville

32806

Forest Investigative Site, Orlando

44718

Forest Investigative Site 013, Canton

45417

Forest Investigative Site, Dayton

48824

Forest Investigative Site, East Lansing

60634

Forest Investigative Site, Chicago

67206

Forest Investigative Site, Wichita

80204

Forest Investigative Site, Denver

80239

Forest Investigative Site, Denver

85254

Forest Investigative Site, Scottsdale

90720

Forest Investigative Site, Los Alamitos

91316

Forest Investigative Site, Encino

92056

Forest Investigative Site, Oceanside

97210

Forest Investigative Site, Portland

98007

Forest Investigative Site, Bellevue

98104

Forest Investigative Site, Seattle

02721

Forest Investigative Site, Fall River

08002

Forest Investigative Site, Cherry Hill

02865

Forest Investigative Site, Lincoln

05091

Forest Investigative Site, Woodstock